Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
IMNM
$22.45
$
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Next Earnings
2026-02-25
Beta
2.106
Average Volume
Market Cap
Last Dividend
CIK
0001472012
ISIN
US45257U1088
CUSIP
45257U108
CEO
Clay Siegall
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
131
IPO Date
2020-10-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Immunome to Present at Upcoming Investor Conferences | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can ac. | Business Wire | 2026-02-23 08:00:00 |
| Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% | Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 million, reflecting both share purchases and price changes. | The Motley Fool | 2026-02-22 13:03:29 |
| Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More | Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the "buy the rumor, sell the news" cliche came in fast and strong, quickly turning the rally into... Here Are Thursday's Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More. | 247 Wallst | 2026-02-12 08:00:49 |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Induce. | Business Wire | 2026-02-05 16:00:00 |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 93,000 shares of common stock to three new employees under the Company's 2024 Indu. | Business Wire | 2026-01-08 16:05:00 |
| Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will b. | Business Wire | 2026-01-06 08:00:00 |
| Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock | Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall purchased 4,729 shares of the firm's stock in a transaction on Tuesday, December 30th. The shares were purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the completion of the transaction, the chief executive officer owned 665,254 shares | Defense World | 2026-01-02 04:52:50 |
| Isaac Barchas Sells 383,200 Shares of Immunome (NASDAQ:IMNM) Stock | Immunome, Inc. (NASDAQ: IMNM - Get Free Report) Director Isaac Barchas sold 383,200 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued | Defense World | 2025-12-25 04:29:03 |
| Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock | Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall acquired 7,278 shares of the company's stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $20.48 per share, with a total value of $149,053.44. Following the purchase, the chief executive officer owned 860,525 shares of the company's | Defense World | 2025-12-23 05:32:42 |
| Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat | Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026. | Seeking Alpha | 2025-12-17 14:44:10 |
| Immunome Announces Pricing of Public Offering of Common Stock | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offe. | Business Wire | 2025-12-16 20:16:00 |
| Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM) | Immunome, Inc. (NASDAQ: IMNM - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase of approximately 347% compared to the typical volume of 650 call options. Wall Street Analysts Forecast Growth A number of analysts recently commented on the | Defense World | 2025-12-16 01:29:18 |
| Why Immunome Stock Surged Today | A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%. | The Motley Fool | 2025-12-15 17:43:27 |
| Immunome Announces Proposed Public Offering of Common Stock | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day. | Business Wire | 2025-12-15 16:01:00 |
| Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA | Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug. | Investors Business Daily | 2025-12-15 10:52:48 |
| Immunome's experimental drug meets main goal in late-stage study | Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor. | Reuters | 2025-12-15 07:16:24 |
| Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors. The trial met its primary endpoint of improving progression-free survival, demonstrating a statistically si. | Business Wire | 2025-12-15 07:00:00 |
| Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors. Webcast, Pres. | Business Wire | 2025-12-14 16:00:00 |
| Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company's 2024 Indu. | Business Wire | 2025-12-04 16:05:00 |
| Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM | Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ: IMNM) by 17.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,565 shares of the company's stock after purchasing an additional 6,141 shares during the period. Intech Investment Management LLC's holdings in | Defense World | 2025-12-01 04:34:49 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| SC 13D/A | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 8-K | 2025-12-17 | 2025-12-17 | View Filing |
| 424B5 | 2025-12-17 | 2025-12-17 | View Filing |
| 424B5 | 2025-12-15 | 2025-12-15 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13G/A | 2025-10-07 | 2025-10-07 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 10-Q | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| SC 13G | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| SC 13G | 2025-07-29 | 2025-07-29 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-03 | 2025-06-03 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| ARS | 2025-04-24 | 2025-04-24 | View Filing |
| DEFA14A | 2025-04-24 | 2025-04-24 | View Filing |
| DEF 14A | 2025-04-24 | 2025-04-24 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-26 | 2025-03-26 | View Filing |
| 4 | 2025-03-26 | 2025-03-26 | View Filing |
| 4 | 2025-03-25 | 2025-03-25 | View Filing |
| 4 | 2025-03-25 | 2025-03-25 | View Filing |
| S-8 | 2025-03-19 | 2025-03-19 | View Filing |
| 10-K | 2025-03-19 | 2025-03-19 | View Filing |
| 8-K | 2025-03-19 | 2025-03-19 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13D/A | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| SC 13G | 2025-02-03 | 2025-02-03 | View Filing |
| SC 13G/A | 2025-01-30 | 2025-01-30 | View Filing |
| 8-K | 2025-01-30 | 2025-01-30 | View Filing |
| 424B5 | 2025-01-30 | 2025-01-30 | View Filing |
| 424B5 | 2025-01-29 | 2025-01-29 | View Filing |
| 8-K | 2025-01-29 | 2025-01-29 | View Filing |
| 8-K | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| S-3ASR | 2024-11-22 | 2024-11-22 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| S-3ASR | 2024-10-08 | 2024-10-08 | View Filing |
| 8-K | 2024-10-08 | 2024-10-07 | View Filing |
| 4 | 2024-09-20 | 2024-09-20 | View Filing |
| SC 13D/A | 2024-08-21 | 2024-08-21 | View Filing |
| 4 | 2024-08-19 | 2024-08-19 | View Filing |
| 4 | 2024-08-19 | 2024-08-19 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 4 | 2024-08-13 | 2024-08-13 | View Filing |
| 10-Q | 2024-08-12 | 2024-08-12 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 3 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Price Action Strategy | 21.76% | 0.96 | 10 | 0.37 | 0.17 | 13.31 |
| Super Trend Strategy | 16.21% | 1.1 | 39 | 0.69 | 5.52 | 7.75 |
| Neural Forcast | 15.53% | 1.1 | 20 | 0.99 | 10.37 | 7.08 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |